nnsm personal page - To The Moon

nnsm

nnsm

No personal profile

16Follow

3Followers

0Topic

0Badge

2021-04-03

$XIAOMI-W(01810)$:D

2021-03-30

Please like and comment

Sorry, the original content has been removed

2021-02-28

?

Sorry, the original content has been removed

2021-02-28

?

Pfizer COVID-19 vaccine reduces transmission after one dose -UK study

2021-02-28

?

Pfizer COVID-19 vaccine reduces transmission after one dose -UK study

2021-02-23

?

Apple Stock This Week: Losing Steam

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3576833752959092,"uuid":"3576833752959092","gmtCreate":1613739729498,"gmtModify":1614522803505,"name":"nnsm","pinyin":"nnsm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":16,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":340527504,"gmtCreate":1617437390508,"gmtModify":1704699698774,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>:D","listText":"<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>:D","text":"$XIAOMI-W(01810)$:D","images":[{"img":"https://static.tigerbbs.com/e78de54da5db0303f2d2620814df29ff","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/340527504","isVote":1,"tweetType":1,"viewCount":236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":355236195,"gmtCreate":1617073997517,"gmtModify":1704801604639,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Please like and comment&nbsp;","listText":"Please like and comment&nbsp;","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/355236195","repostId":"2123269962","repostType":4,"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366525581,"gmtCreate":1614518030343,"gmtModify":1704772211627,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366525581","repostId":"1150278371","repostType":4,"isVote":1,"tweetType":1,"viewCount":218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366525677,"gmtCreate":1614517968699,"gmtModify":1704772211788,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366525677","repostId":"2114371822","repostType":4,"repost":{"id":"2114371822","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614335051,"share":"https://www.laohu8.com/m/news/2114371822?lang=&edition=full","pubTime":"2021-02-26 18:24","market":"us","language":"en","title":"Pfizer COVID-19 vaccine reduces transmission after one dose -UK study","url":"https://stock-news.laohu8.com/highlight/detail?id=2114371822","media":"Reuters","summary":"LONDON, Feb 26  - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare ","content":"<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer COVID-19 vaccine reduces transmission after one dose -UK study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer COVID-19 vaccine reduces transmission after one dose -UK study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114371822","content_text":"LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.\nResearchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.\n“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.\nAfter separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.\nThis compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.\nThe study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.\nThis suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.\nThe level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.\nBritain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.\n“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”\nKey real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366522493,"gmtCreate":1614517568112,"gmtModify":1704772210648,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366522493","repostId":"2114371822","repostType":4,"repost":{"id":"2114371822","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614335051,"share":"https://www.laohu8.com/m/news/2114371822?lang=&edition=full","pubTime":"2021-02-26 18:24","market":"us","language":"en","title":"Pfizer COVID-19 vaccine reduces transmission after one dose -UK study","url":"https://stock-news.laohu8.com/highlight/detail?id=2114371822","media":"Reuters","summary":"LONDON, Feb 26  - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare ","content":"<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer COVID-19 vaccine reduces transmission after one dose -UK study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer COVID-19 vaccine reduces transmission after one dose -UK study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114371822","content_text":"LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.\nResearchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.\n“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.\nAfter separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.\nThis compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.\nThe study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.\nThis suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.\nThe level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.\nBritain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.\n“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”\nKey real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369505866,"gmtCreate":1614054719655,"gmtModify":1704887395571,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/369505866","repostId":"1145339995","repostType":4,"repost":{"id":"1145339995","pubTimestamp":1614048887,"share":"https://www.laohu8.com/m/news/1145339995?lang=&edition=full","pubTime":"2021-02-23 10:54","market":"us","language":"en","title":"Apple Stock This Week: Losing Steam","url":"https://stock-news.laohu8.com/highlight/detail?id=1145339995","media":"TheStreet","summary":"Apple stock has been quietly underperforming its key benchmarks in 2021. The problem does not seem t","content":"<p>Apple stock has been quietly underperforming its key benchmarks in 2021. The problem does not seem to be with business fundamentals, but with market sentiment instead.</p>\n<p>Quietly, Apple continues to underperform in 2021.</p>\n<p>Over the past four trading days (last Monday was President’s Day and the stock market was closed), shares of the Cupertino company declined about 4%. None of the main peer groups, including the consumer discretionary and tech sectors, performed this poorly.</p>\n<p>See chart below – Apple is the blue line.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33a1b3fafec7dc8155390e2d4094da04\" tg-width=\"1240\" tg-height=\"649\"><span>Stock Rover</span></p>\n<p>The full-year picture has not looked much more promising, at least so far. Apple shares rallied ahead of its fiscal first quarter earnings day, which was&nbsp;covered in detailed by the Apple Maven&nbsp;a few weeks ago. Towards the end of January, Apple had gained more than its key benchmarks year-to-date. See graph below.</p>\n<p>However,the “sell the news” pullback that I warned about&nbsp;on January 28 took place. From last month’s peak, Apple has already dipped 9%. Shares are on the verge of entering correction territory once again.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cbf13d3b9fd7cebae67624cd78f9f09\" tg-width=\"1240\" tg-height=\"630\"><span>Stock Rover</span></p>\n<p><b>Not about the fundamentals</b></p>\n<p>I find it hard to believe that any of the recent weakness in Apple stock has anything to do with fundamentals.Think of the company’s earnings results, for example.</p>\n<p>The iPhone staged an impressive comeback, with revenues climbing 17% during the holiday period after a disappointing fiscal fourth quarter. China also showed signs of life at last, as sales increased a whopping 57% in the region. Margins expanded on the back of gains of scale and a more favorable product mix. The company’s balance sheet is flush with cash.</p>\n<p>What’s not to like about Apple’s business?</p>\n<p><b>A sentiment problem</b></p>\n<p>The problem with Apple shares so far this year, in my view, are two.</p>\n<p>First, the stock seems to have caught too strong of a tailwind in the past couple of months:once from the Apple Car buzz, in late December, and again as investors anticipated a blowout holiday quarter in 2020. Therefore, it was reasonable to see shares adjust to what may be a more reasonable price below the $130 mark.</p>\n<p>Second, 2021 has been a year to bet on recovery stocks, not high-quality growth names like Apple. Notice below how small cap and high-beta stocks (tickers IWM and SPHB) have lavishly outperformed the high-quality ETF and the Nasdaq (tickers QUAL and QQQ) so far this year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fdbaae21b1a60bfe8ced185756760c51\" tg-width=\"1240\" tg-height=\"647\"><span>Stock Rover</span></p>\n<p><b>The Buffett effect</b></p>\n<p>The most recent event that helped to push Apple shares lower was&nbsp;Berkshire Hathaway’s disclosure of its portfolio holdings, as of the end of 2020. Warren Buffett’s company sold about $7.4 billion worth of Apple shares in the last quarter.</p>\n<p>As I explained, the move seemed to be a position trim rather than a bearish statement. I do not believe that investors should be concerned about Apple losing the Buffett seal of approval, especially considering the still massive 43% allocation of Berkshire’s portfolio to the Cupertino company.</p>\n<p>Yet, the market is the market, and it chose to punish Apple stock even further, following the release of Berkshire’s most recent 13-F filing.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock This Week: Losing Steam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock This Week: Losing Steam\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-23 10:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/news/apple-stock-this-week-losing-steam><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple stock has been quietly underperforming its key benchmarks in 2021. The problem does not seem to be with business fundamentals, but with market sentiment instead.\nQuietly, Apple continues to ...</p>\n\n<a href=\"https://www.thestreet.com/apple/news/apple-stock-this-week-losing-steam\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/news/apple-stock-this-week-losing-steam","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145339995","content_text":"Apple stock has been quietly underperforming its key benchmarks in 2021. The problem does not seem to be with business fundamentals, but with market sentiment instead.\nQuietly, Apple continues to underperform in 2021.\nOver the past four trading days (last Monday was President’s Day and the stock market was closed), shares of the Cupertino company declined about 4%. None of the main peer groups, including the consumer discretionary and tech sectors, performed this poorly.\nSee chart below – Apple is the blue line.\nStock Rover\nThe full-year picture has not looked much more promising, at least so far. Apple shares rallied ahead of its fiscal first quarter earnings day, which was covered in detailed by the Apple Maven a few weeks ago. Towards the end of January, Apple had gained more than its key benchmarks year-to-date. See graph below.\nHowever,the “sell the news” pullback that I warned about on January 28 took place. From last month’s peak, Apple has already dipped 9%. Shares are on the verge of entering correction territory once again.\nStock Rover\nNot about the fundamentals\nI find it hard to believe that any of the recent weakness in Apple stock has anything to do with fundamentals.Think of the company’s earnings results, for example.\nThe iPhone staged an impressive comeback, with revenues climbing 17% during the holiday period after a disappointing fiscal fourth quarter. China also showed signs of life at last, as sales increased a whopping 57% in the region. Margins expanded on the back of gains of scale and a more favorable product mix. The company’s balance sheet is flush with cash.\nWhat’s not to like about Apple’s business?\nA sentiment problem\nThe problem with Apple shares so far this year, in my view, are two.\nFirst, the stock seems to have caught too strong of a tailwind in the past couple of months:once from the Apple Car buzz, in late December, and again as investors anticipated a blowout holiday quarter in 2020. Therefore, it was reasonable to see shares adjust to what may be a more reasonable price below the $130 mark.\nSecond, 2021 has been a year to bet on recovery stocks, not high-quality growth names like Apple. Notice below how small cap and high-beta stocks (tickers IWM and SPHB) have lavishly outperformed the high-quality ETF and the Nasdaq (tickers QUAL and QQQ) so far this year.\nStock Rover\nThe Buffett effect\nThe most recent event that helped to push Apple shares lower was Berkshire Hathaway’s disclosure of its portfolio holdings, as of the end of 2020. Warren Buffett’s company sold about $7.4 billion worth of Apple shares in the last quarter.\nAs I explained, the move seemed to be a position trim rather than a bearish statement. I do not believe that investors should be concerned about Apple losing the Buffett seal of approval, especially considering the still massive 43% allocation of Berkshire’s portfolio to the Cupertino company.\nYet, the market is the market, and it chose to punish Apple stock even further, following the release of Berkshire’s most recent 13-F filing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":355236195,"gmtCreate":1617073997517,"gmtModify":1704801604639,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Please like and comment&nbsp;","listText":"Please like and comment&nbsp;","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/355236195","repostId":"2123269962","repostType":4,"repost":{"id":"2123269962","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1617072060,"share":"https://www.laohu8.com/m/news/2123269962?lang=&edition=full","pubTime":"2021-03-30 10:41","market":"us","language":"en","title":"Micron earnings: Semiconductor shortage leads to heightened expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2123269962","media":"Dow Jones","summary":"Earnings preview: Greater demand for memory chips during COVID-19 pandemic pushed Micron to increase its forecast. Micron Technology Inc. faces a heightened bar of its own making for the rest of the year, as widespread chip shortages push up prices for its core memory chips.Micron $$ is scheduled to report fiscal second-quarter earnings results after the close of markets Wednesday. The Boise, Idaho-based chip maker considerably raised its forecast for the second quarter  earlier this month, sett","content":"<p>MW Micron earnings: Semiconductor shortage leads to heightened expectations</p><p>By Wallace Witkowski</p><p>Earnings preview: Greater demand for memory chips during COVID-19 pandemic pushed Micron to increase its forecast</p><p>Micron Technology Inc. faces a heightened bar of its own making for the rest of the year, as widespread chip shortages push up prices for its core memory chips.</p><p>Micron <a href=\"https://laohu8.com/S/MU\">$(MU)$</a> is scheduled to report fiscal second-quarter earnings results after the close of markets Wednesday. The Boise, Idaho-based chip maker considerably raised its forecast for the second quarter  earlier this month, setting up expectations for the rest of the year.</p><p>The big gain in sales is largely the result of the global semiconductor shortage that developed amid heightened demand during the COVID-19 pandemic. Micron could see revenue surge by more than $1 billion from its core memory products, and analysts expect those types of gains to continue throughout 2021.</p><p>Read: Worldwide chip shortage expected to last into next year, and that's good news for semiconductor stocks</p><p>Micron specializes in DRAM and NAND memory chips. DRAM, or dynamic random access memory, is the type of memory commonly used in PCs and servers, while NAND chips are the flash memory chips used in smaller devices like smartphones and USB drives.</p><p>Analysts on average expect DRAM sales of $4.3 billion, up from $3.08 billion in the year-ago period, and NAND sales of $1.6 billion, up from last year's $1.51 billion, according to FactSet.</p><p>Mizuho analyst Vijay Rakesh, who has a buy rating on Micron and a $100 price target, said he sees the the second half of 2021 as an exceptional cycle for memory-chip makers as \"growth shows more potential upside after recovering frompricing and data center demand headwinds in 2H20/1H21.\"</p><p>Rakesh said that DRAM pricing for PCs are expected to rise 19% from a year ago, when prices dropped 17% year-over-year. NAND prices are expected to remain stable and possibly recover a bit, with 5G-device launches as a tailwind.</p><p>Ahead of the report, the company said it was dropping development of 3D XPoint technology  in order to focus on compute-express link chips for data centers.</p><p>What to expect</p><p>Earnings: Micron on average is expected to post adjusted earnings of 95 cents a share, up sharply from 66 cents a share expected at the beginning of the quarter, based on 29 analysts surveyed by FactSet. Micron forecast earnings of 93 cents to 98 cents a share at the beginning of March, up from its previous forecast of 68 cents to 72 cents a share . Estimize, a software platform that uses crowdsourcing from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 98 cents a share.</p><p>Revenue: Wall Street expects revenue of $6.19 billion from Micron, according to 28 analysts polled by FactSet. That's up from the $5.54 billion forecast at the beginning of the quarter. Micron predicted revenue of $6.2 billion to $6.25 billion at the beginning of March, up from its previous forecast of $5.6 billion to $6 billion. Estimize expects revenue of $6.26 billion.</p><p>Stock movement: Over Micron's fiscal second quarter, the stock rose nearly 21%, compared with a 4.3% increase on the PHLX Semiconductor Index  over the same period, a 1.9% rise by the S&amp;P 500 index  and a 2.8% gain by the Nasdaq Composite Index . Micron shares closed at $94.60 on March 1, their highest closing price in more than 20 years.</p><p>What analysts are saying</p><p>Evercore ISI analyst C.J. Muse, who has an outperform rating and a $135 price target, said in a note related to Micron's hiked forecast that broader chip shortages will keep demand high.</p><p>\"Longer-term, with management calling out undersupply for DRAM through all of CY21 (and even hinting this could continue into CY22) and falling NAND inventories leading to a higher likelihood of a turnaround there, we see a strong roadmap for estimates to continue moving higher through-out CY21,\" Muse said.</p><p>UBS analyst Timothy Arcuri, who has a buy rating, said a recent discussion with a former Micron executive indicated that the company's lesser exposure to NAND compared with competitors gave it an advantage while it stands to benefit from continued high DRAM demand.</p><p>\"DRAM consolidation has played out and Samsung, Hynix &amp; MU are behaving rationally, even as demand remains robust to the point where it is plausible that hyperscalers may consider pre-paying for supply,\" Arcuri said.</p><p>Of the 34 analysts who cover Micron, 28 have buy or overweight ratings, and six have hold ratings, with an average price target of $114.86.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Micron earnings: Semiconductor shortage leads to heightened expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicron earnings: Semiconductor shortage leads to heightened expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-03-30 10:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Micron earnings: Semiconductor shortage leads to heightened expectations</p><p>By Wallace Witkowski</p><p>Earnings preview: Greater demand for memory chips during COVID-19 pandemic pushed Micron to increase its forecast</p><p>Micron Technology Inc. faces a heightened bar of its own making for the rest of the year, as widespread chip shortages push up prices for its core memory chips.</p><p>Micron <a href=\"https://laohu8.com/S/MU\">$(MU)$</a> is scheduled to report fiscal second-quarter earnings results after the close of markets Wednesday. The Boise, Idaho-based chip maker considerably raised its forecast for the second quarter  earlier this month, setting up expectations for the rest of the year.</p><p>The big gain in sales is largely the result of the global semiconductor shortage that developed amid heightened demand during the COVID-19 pandemic. Micron could see revenue surge by more than $1 billion from its core memory products, and analysts expect those types of gains to continue throughout 2021.</p><p>Read: Worldwide chip shortage expected to last into next year, and that's good news for semiconductor stocks</p><p>Micron specializes in DRAM and NAND memory chips. DRAM, or dynamic random access memory, is the type of memory commonly used in PCs and servers, while NAND chips are the flash memory chips used in smaller devices like smartphones and USB drives.</p><p>Analysts on average expect DRAM sales of $4.3 billion, up from $3.08 billion in the year-ago period, and NAND sales of $1.6 billion, up from last year's $1.51 billion, according to FactSet.</p><p>Mizuho analyst Vijay Rakesh, who has a buy rating on Micron and a $100 price target, said he sees the the second half of 2021 as an exceptional cycle for memory-chip makers as \"growth shows more potential upside after recovering frompricing and data center demand headwinds in 2H20/1H21.\"</p><p>Rakesh said that DRAM pricing for PCs are expected to rise 19% from a year ago, when prices dropped 17% year-over-year. NAND prices are expected to remain stable and possibly recover a bit, with 5G-device launches as a tailwind.</p><p>Ahead of the report, the company said it was dropping development of 3D XPoint technology  in order to focus on compute-express link chips for data centers.</p><p>What to expect</p><p>Earnings: Micron on average is expected to post adjusted earnings of 95 cents a share, up sharply from 66 cents a share expected at the beginning of the quarter, based on 29 analysts surveyed by FactSet. Micron forecast earnings of 93 cents to 98 cents a share at the beginning of March, up from its previous forecast of 68 cents to 72 cents a share . Estimize, a software platform that uses crowdsourcing from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 98 cents a share.</p><p>Revenue: Wall Street expects revenue of $6.19 billion from Micron, according to 28 analysts polled by FactSet. That's up from the $5.54 billion forecast at the beginning of the quarter. Micron predicted revenue of $6.2 billion to $6.25 billion at the beginning of March, up from its previous forecast of $5.6 billion to $6 billion. Estimize expects revenue of $6.26 billion.</p><p>Stock movement: Over Micron's fiscal second quarter, the stock rose nearly 21%, compared with a 4.3% increase on the PHLX Semiconductor Index  over the same period, a 1.9% rise by the S&amp;P 500 index  and a 2.8% gain by the Nasdaq Composite Index . Micron shares closed at $94.60 on March 1, their highest closing price in more than 20 years.</p><p>What analysts are saying</p><p>Evercore ISI analyst C.J. Muse, who has an outperform rating and a $135 price target, said in a note related to Micron's hiked forecast that broader chip shortages will keep demand high.</p><p>\"Longer-term, with management calling out undersupply for DRAM through all of CY21 (and even hinting this could continue into CY22) and falling NAND inventories leading to a higher likelihood of a turnaround there, we see a strong roadmap for estimates to continue moving higher through-out CY21,\" Muse said.</p><p>UBS analyst Timothy Arcuri, who has a buy rating, said a recent discussion with a former Micron executive indicated that the company's lesser exposure to NAND compared with competitors gave it an advantage while it stands to benefit from continued high DRAM demand.</p><p>\"DRAM consolidation has played out and Samsung, Hynix &amp; MU are behaving rationally, even as demand remains robust to the point where it is plausible that hyperscalers may consider pre-paying for supply,\" Arcuri said.</p><p>Of the 34 analysts who cover Micron, 28 have buy or overweight ratings, and six have hold ratings, with an average price target of $114.86.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f5e8aba7de194dc92d26747c1cfec057","relate_stocks":{"MU":"美光科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2123269962","content_text":"MW Micron earnings: Semiconductor shortage leads to heightened expectationsBy Wallace WitkowskiEarnings preview: Greater demand for memory chips during COVID-19 pandemic pushed Micron to increase its forecastMicron Technology Inc. faces a heightened bar of its own making for the rest of the year, as widespread chip shortages push up prices for its core memory chips.Micron $(MU)$ is scheduled to report fiscal second-quarter earnings results after the close of markets Wednesday. The Boise, Idaho-based chip maker considerably raised its forecast for the second quarter  earlier this month, setting up expectations for the rest of the year.The big gain in sales is largely the result of the global semiconductor shortage that developed amid heightened demand during the COVID-19 pandemic. Micron could see revenue surge by more than $1 billion from its core memory products, and analysts expect those types of gains to continue throughout 2021.Read: Worldwide chip shortage expected to last into next year, and that's good news for semiconductor stocksMicron specializes in DRAM and NAND memory chips. DRAM, or dynamic random access memory, is the type of memory commonly used in PCs and servers, while NAND chips are the flash memory chips used in smaller devices like smartphones and USB drives.Analysts on average expect DRAM sales of $4.3 billion, up from $3.08 billion in the year-ago period, and NAND sales of $1.6 billion, up from last year's $1.51 billion, according to FactSet.Mizuho analyst Vijay Rakesh, who has a buy rating on Micron and a $100 price target, said he sees the the second half of 2021 as an exceptional cycle for memory-chip makers as \"growth shows more potential upside after recovering frompricing and data center demand headwinds in 2H20/1H21.\"Rakesh said that DRAM pricing for PCs are expected to rise 19% from a year ago, when prices dropped 17% year-over-year. NAND prices are expected to remain stable and possibly recover a bit, with 5G-device launches as a tailwind.Ahead of the report, the company said it was dropping development of 3D XPoint technology  in order to focus on compute-express link chips for data centers.What to expectEarnings: Micron on average is expected to post adjusted earnings of 95 cents a share, up sharply from 66 cents a share expected at the beginning of the quarter, based on 29 analysts surveyed by FactSet. Micron forecast earnings of 93 cents to 98 cents a share at the beginning of March, up from its previous forecast of 68 cents to 72 cents a share . Estimize, a software platform that uses crowdsourcing from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 98 cents a share.Revenue: Wall Street expects revenue of $6.19 billion from Micron, according to 28 analysts polled by FactSet. That's up from the $5.54 billion forecast at the beginning of the quarter. Micron predicted revenue of $6.2 billion to $6.25 billion at the beginning of March, up from its previous forecast of $5.6 billion to $6 billion. Estimize expects revenue of $6.26 billion.Stock movement: Over Micron's fiscal second quarter, the stock rose nearly 21%, compared with a 4.3% increase on the PHLX Semiconductor Index  over the same period, a 1.9% rise by the S&P 500 index  and a 2.8% gain by the Nasdaq Composite Index . Micron shares closed at $94.60 on March 1, their highest closing price in more than 20 years.What analysts are sayingEvercore ISI analyst C.J. Muse, who has an outperform rating and a $135 price target, said in a note related to Micron's hiked forecast that broader chip shortages will keep demand high.\"Longer-term, with management calling out undersupply for DRAM through all of CY21 (and even hinting this could continue into CY22) and falling NAND inventories leading to a higher likelihood of a turnaround there, we see a strong roadmap for estimates to continue moving higher through-out CY21,\" Muse said.UBS analyst Timothy Arcuri, who has a buy rating, said a recent discussion with a former Micron executive indicated that the company's lesser exposure to NAND compared with competitors gave it an advantage while it stands to benefit from continued high DRAM demand.\"DRAM consolidation has played out and Samsung, Hynix & MU are behaving rationally, even as demand remains robust to the point where it is plausible that hyperscalers may consider pre-paying for supply,\" Arcuri said.Of the 34 analysts who cover Micron, 28 have buy or overweight ratings, and six have hold ratings, with an average price target of $114.86.","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366525677,"gmtCreate":1614517968699,"gmtModify":1704772211788,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366525677","repostId":"2114371822","repostType":4,"repost":{"id":"2114371822","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614335051,"share":"https://www.laohu8.com/m/news/2114371822?lang=&edition=full","pubTime":"2021-02-26 18:24","market":"us","language":"en","title":"Pfizer COVID-19 vaccine reduces transmission after one dose -UK study","url":"https://stock-news.laohu8.com/highlight/detail?id=2114371822","media":"Reuters","summary":"LONDON, Feb 26  - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare ","content":"<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer COVID-19 vaccine reduces transmission after one dose -UK study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer COVID-19 vaccine reduces transmission after one dose -UK study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114371822","content_text":"LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.\nResearchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.\n“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.\nAfter separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.\nThis compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.\nThe study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.\nThis suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.\nThe level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.\nBritain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.\n“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”\nKey real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366522493,"gmtCreate":1614517568112,"gmtModify":1704772210648,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366522493","repostId":"2114371822","repostType":4,"repost":{"id":"2114371822","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614335051,"share":"https://www.laohu8.com/m/news/2114371822?lang=&edition=full","pubTime":"2021-02-26 18:24","market":"us","language":"en","title":"Pfizer COVID-19 vaccine reduces transmission after one dose -UK study","url":"https://stock-news.laohu8.com/highlight/detail?id=2114371822","media":"Reuters","summary":"LONDON, Feb 26  - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare ","content":"<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer COVID-19 vaccine reduces transmission after one dose -UK study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer COVID-19 vaccine reduces transmission after one dose -UK study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.</p>\n<p>Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.</p>\n<p>“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.</p>\n<p>After separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.</p>\n<p>This compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.</p>\n<p>The study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.</p>\n<p>This suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.</p>\n<p>The level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.</p>\n<p>Britain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.</p>\n<p>“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”</p>\n<p>Key real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114371822","content_text":"LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.\nResearchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.\n“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.\nAfter separating the test results from unvaccinated and vaccinated staff, Jones’ team found that 0.80% tests from unvaccinated healthcare workers were positive.\nThis compared with 0.37% of tests from staff less than 12 days post-vaccination - when the vaccine’s protective effect is not yet fully established - and 0.20% of tests from staff at 12 days or more post-vaccination.\nThe study and its results have yet to be independently peer-reviewed by other scientists, but were published online as a preprint on Friday.\nThis suggests a four-fold decrease in the risk of asymptomatic COVID-19 infection amongst healthcare workers who have been vaccinated for more than 12 days, and 75% protection, said Mike Weekes, an infectious disease specialist at Cambridge University’s department of medicine, who co-led the study.\nThe level of asymptomatic infection was also halved in those vaccinated for less than 12 days, he said.\nBritain has been rolling out vaccinations with both the Pfizer COVID-19 shot and one from AstraZeneca since late December 2020.\n“This is great news – the Pfizer vaccine not only provides protection against becoming ill from SARS-CoV-2, but also helps prevent infection, reducing the potential for the virus to be passed on to others,” Weeks said. “But we have to remember that the vaccine doesn’t give complete protection for everyone.”\nKey real-world data published on Wednesday from Israel, which has conducted one of the world’s fastest rollouts of Pfizer’s COVID-19 vaccine, showed that two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.","news_type":1},"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340527504,"gmtCreate":1617437390508,"gmtModify":1704699698774,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>:D","listText":"<a href=\"https://laohu8.com/S/01810\">$XIAOMI-W(01810)$</a>:D","text":"$XIAOMI-W(01810)$:D","images":[{"img":"https://static.tigerbbs.com/e78de54da5db0303f2d2620814df29ff","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/340527504","isVote":1,"tweetType":1,"viewCount":236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":366525581,"gmtCreate":1614518030343,"gmtModify":1704772211627,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366525581","repostId":"1150278371","repostType":4,"repost":{"id":"1150278371","pubTimestamp":1614332308,"share":"https://www.laohu8.com/m/news/1150278371?lang=&edition=full","pubTime":"2021-02-26 17:38","market":"us","language":"en","title":"Why NVIDIA Shares Stumbled, After an Impressive Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1150278371","media":"Motley Fool","summary":"The soaring stock was arguably due for a correction, and some investors worry that the end of this c","content":"<p>The soaring stock was arguably due for a correction, and some investors worry that the end of this cryptocurrency boom could hurt NVIDIA's business.</p><p><b>What happened</b></p><p>Semiconductor developer&nbsp;<b>NVIDIA</b>&nbsp;(NASDAQ:NVDA)&nbsp;posted strong fourth-quarter results last night with a side of optimistic guidance for the next reporting period. The stock fell as much as 8.2% on Thursday anyhow, because sometimes even an analyst-stumping report isn't quite enough to support a&nbsp;skyrocketing stock&nbsp;like NVIDIA's.</p><p><b>So what</b></p><p>In the fourth quarter of 2020, NVIDIA's top-line revenue rose 62% year over year to $5 billion. Adjusted earnings climbed 64% higher, landing at $3.10 per diluted share. Your average analyst would have settled for earnings near $2.81 per share on sales in the neighborhood of $4.82 billion. The stellar results were driven by high demand for NVIDIA's data center processors and gaming products.</p><p>Heading into the report, NVIDIA's shares had gained 112% in 52 weeks. The stock traded at a nosebleed-inducing 95 times trailing earnings and 86 times&nbsp;free cash flow, setting the stage for a significant price cut despite a strong earnings report. Today, you can pick up NVIDIA's shares for the somewhat less exorbitant valuation ratios of 93 times adjusted earnings or 71 times free cash flow.</p><p><b>Now what</b></p><p>Some investors also worry about artificial growth stemming from rising cryptocurrency prices. Specifically, NVIDIA's graphics processors are very efficient at mining&nbsp;<b>Ethereum</b>(CRYPTO:ETH)&nbsp;tokens and the smart-contract cryptocurrency has seen prices skyrocket 568% over the last year. If Ethereum miners are buying tons of NVIDIA's graphics cards, that leaves fewer units on store shelves for actual gamers. All of this is happening during a marketwide&nbsp;shortage of semiconductor manufacturing capacity, limiting the processor supplies even further. All of this sounds like good news for NVIDIA, but the idea is that it also exposes the company to significant market risks if Ethereum prices crash again, killing the demand for token-mining hardware.</p><p>NVIDIA's management has acknowledged this concern and&nbsp;taken steps to limit the Ethereum-mining appeal of its gaming hardware. Furthermore, CEO Jensen Huang argues that the cryptocurrency mining market is a fairly small part of his company's end-user market. Hyper-specialized application-specific integrated circuits (ASICs) play a much larger role in the crypto-mining sector.</p><p>\"I think that this is going to be a part of our business. It won't grow extremely large no matter what happens and the reason for that is because when it starts to grow large, more ASICs come to the market, which kinds of mutes it,\" Huang said on the fourth-quarter earnings call. \"When the market becomes smaller, it's harder for ASICs to sustain the R&amp;D and so the spot miners, industrial miners come back and then we'll create [cryptocurrency mining processors]. And so we expect it to be a small part of our business as we go forward. \"</p><p>The company can't track how people end up using the chips it sells, but Huang estimates that roughly $200 million of this quarter's gaming product sales came from mining enthusiasts. That's just 8% of a $2.5 billion top-line haul.</p><p>All of this is to say that NVIDIA's post-earnings correction may have been amplified by the Ethereum mining risk, and that particular threat doesn't look all that menacing. Therefore, you could make a case that NVIDIA's shares are selling at a discount today -- despite the sky-high valuation ratios.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why NVIDIA Shares Stumbled, After an Impressive Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy NVIDIA Shares Stumbled, After an Impressive Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-26 17:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/02/25/why-nvidia-shares-stumbled-today-after-an-impressi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The soaring stock was arguably due for a correction, and some investors worry that the end of this cryptocurrency boom could hurt NVIDIA's business.What happenedSemiconductor developer NVIDIA (NASDAQ:...</p>\n\n<a href=\"https://www.fool.com/investing/2021/02/25/why-nvidia-shares-stumbled-today-after-an-impressi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/02/25/why-nvidia-shares-stumbled-today-after-an-impressi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150278371","content_text":"The soaring stock was arguably due for a correction, and some investors worry that the end of this cryptocurrency boom could hurt NVIDIA's business.What happenedSemiconductor developer NVIDIA (NASDAQ:NVDA) posted strong fourth-quarter results last night with a side of optimistic guidance for the next reporting period. The stock fell as much as 8.2% on Thursday anyhow, because sometimes even an analyst-stumping report isn't quite enough to support a skyrocketing stock like NVIDIA's.So whatIn the fourth quarter of 2020, NVIDIA's top-line revenue rose 62% year over year to $5 billion. Adjusted earnings climbed 64% higher, landing at $3.10 per diluted share. Your average analyst would have settled for earnings near $2.81 per share on sales in the neighborhood of $4.82 billion. The stellar results were driven by high demand for NVIDIA's data center processors and gaming products.Heading into the report, NVIDIA's shares had gained 112% in 52 weeks. The stock traded at a nosebleed-inducing 95 times trailing earnings and 86 times free cash flow, setting the stage for a significant price cut despite a strong earnings report. Today, you can pick up NVIDIA's shares for the somewhat less exorbitant valuation ratios of 93 times adjusted earnings or 71 times free cash flow.Now whatSome investors also worry about artificial growth stemming from rising cryptocurrency prices. Specifically, NVIDIA's graphics processors are very efficient at mining Ethereum(CRYPTO:ETH) tokens and the smart-contract cryptocurrency has seen prices skyrocket 568% over the last year. If Ethereum miners are buying tons of NVIDIA's graphics cards, that leaves fewer units on store shelves for actual gamers. All of this is happening during a marketwide shortage of semiconductor manufacturing capacity, limiting the processor supplies even further. All of this sounds like good news for NVIDIA, but the idea is that it also exposes the company to significant market risks if Ethereum prices crash again, killing the demand for token-mining hardware.NVIDIA's management has acknowledged this concern and taken steps to limit the Ethereum-mining appeal of its gaming hardware. Furthermore, CEO Jensen Huang argues that the cryptocurrency mining market is a fairly small part of his company's end-user market. Hyper-specialized application-specific integrated circuits (ASICs) play a much larger role in the crypto-mining sector.\"I think that this is going to be a part of our business. It won't grow extremely large no matter what happens and the reason for that is because when it starts to grow large, more ASICs come to the market, which kinds of mutes it,\" Huang said on the fourth-quarter earnings call. \"When the market becomes smaller, it's harder for ASICs to sustain the R&D and so the spot miners, industrial miners come back and then we'll create [cryptocurrency mining processors]. And so we expect it to be a small part of our business as we go forward. \"The company can't track how people end up using the chips it sells, but Huang estimates that roughly $200 million of this quarter's gaming product sales came from mining enthusiasts. That's just 8% of a $2.5 billion top-line haul.All of this is to say that NVIDIA's post-earnings correction may have been amplified by the Ethereum mining risk, and that particular threat doesn't look all that menacing. Therefore, you could make a case that NVIDIA's shares are selling at a discount today -- despite the sky-high valuation ratios.","news_type":1},"isVote":1,"tweetType":1,"viewCount":218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369505866,"gmtCreate":1614054719655,"gmtModify":1704887395571,"author":{"id":"3576833752959092","authorId":"3576833752959092","name":"nnsm","avatar":"https://static.tigerbbs.com/3837b1a695ebe51d68a84ca8c4a5738f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/369505866","repostId":"1145339995","repostType":4,"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}